Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Additive that makes juices ’tart’ quadruples yield of essential hemophilia treatment

28.08.2002


Citric acid may help alleviate chronic shortages of critical clotting factor



The common additive that gives "tartness" to orange juice, lemon juice and sodas also can dramatically boost the production of a protein critical for treating victims of hemophilia and other bleeding disorders, a UC Irvine study has found.

The findings indicate that citric acid, the juice additive, may help alleviate recurring shortages of a protein called Factor VIII, which is important for the normal clotting of blood and is missing in most victims of hemophilia, a genetic bleeding disorder. The findings were presented at the Congress of the International Society of Blood Transfusion in Vancouver, British Columbia.


UCI researcher John Owens and Dr. Edward Shanbrom, one of the inventors of the first clinical treatment for hemophilia 35 years ago, found that adding small amounts of citric acid compounds to blood plasma produced four times the level of Factor VIII and other crucial clotting proteins compared to current extraction methods.

"Treatment of hemophilia has relied on transfusing patients with clotting factors to raise their levels in the blood and prevent excessive bleeding," Shanbrom said. "But current methods of extracting the proteins from blood plasma don’t produce enough clotting factor. New therapies involve going through the contortions of using recombinant DNA to produce proteins from Chinese hamster ovary cells and purifying them in mouse cancer cells. These therapies are prohibitively expensive and not any safer from contamination. Thus, we have an acute need for an inexpensive and safe way to produce hemophilia treatments."

Hemophilia is the oldest known genetic bleeding disorder and is marked by excessive bleeding, inadequate blood clotting and, in severe cases, irreversible joint damage and life-threatening hemorrhages. It almost always appears in men, though women can be carriers of the disease-causing mutation.

There are two types of the disease: Hemophilia A is the most common, affecting one in 5,000 men worldwide. It is caused by a mutation that prevents normal production in the body of the Factor VIII clotting protein. Hemophilia B is less common and is caused by low levels of another clotting protein, Factor IX. Both are treated with transfusions of clotting factors, either from human blood or from using new recombinant DNA techniques.

The researchers found that adding citric acid to the plasma before starting the production of clotting factors, a process known as cryoprecipitation, produced a yield of 97 percent of total plasma levels of Factor VIII, compared to about 25 percent of plasma levels for normal production. Other proteins important for clotting, such as fibrinogen and von Willebrand’s Factor, also had yields of about 97 percent.

"A standard 250 milliliter unit of plasma yielded 10 times more clotting factor than what current extraction methods yield," Owens said. "We believe that citric acid seems to act as a ’primer,’ allowing for more of these factors to be harvested from plasma. Citric acid not only helped produce higher levels of these factors, but also produced high levels of other proteins important in surgical procedures, such as fibrinogen, fibrin glue and sealant."

In addition to helping resolve shortages in clotting factor supplies, the researchers also are looking at ways to reduce contamination of transfused blood, including clotting factors. In the past decades, transfused blood has transmitted bacteria and viruses, including those causing AIDS and tuberculosis, to patients. Shanbrom, who also developed the first method of protecting blood from contamination, and the UCI researchers suspect that citric acid may aid in preventing contamination and infection from blood transfusions, because the acid is a potent antibiotic and is used to preserve foods and pharmaceuticals.

Owens and Shanbrom are now looking at ways to make their method, called "Super-Cryoprecipitate," commercially available and are exploring methods to ensure the safety of transfusions of clotting factors. One method under study involves pouring treated blood plasma into a column containing iodine, which may help prevent viral and bacterial infections.

Owens’ and Shanbrom’s colleagues include Dr. Thomas Cesario, dean of the College of Medicine, and Dr. Jose Ocariz, director of UCI Medical Center’s Transfusion Service.

Andrew Porterfield | EurekAlert!
Further information:
http://www.uci.edu/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

 
Latest News

New switch decides between genome repair and death of cells

27.09.2016 | Life Sciences

Nanotechnology for energy materials: Electrodes like leaf veins

27.09.2016 | Physics and Astronomy

‘Missing link’ found in the development of bioelectronic medicines

27.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>